nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—CYP3A4—Cytarabine—lymphatic system cancer	0.00785	0.318	CbGbCtD
Fulvestrant—CYP3A4—Teniposide—lymphatic system cancer	0.00773	0.313	CbGbCtD
Fulvestrant—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00615	0.00631	CcSEcCtD
Fulvestrant—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00605	0.0062	CcSEcCtD
Fulvestrant—Anorexia—Mechlorethamine—lymphatic system cancer	0.00594	0.00609	CcSEcCtD
Fulvestrant—Injury—Carmustine—lymphatic system cancer	0.00572	0.00586	CcSEcCtD
Fulvestrant—Haemoglobin—Fludarabine—lymphatic system cancer	0.00571	0.00585	CcSEcCtD
Fulvestrant—Haemorrhage—Fludarabine—lymphatic system cancer	0.00568	0.00582	CcSEcCtD
Fulvestrant—Pharyngitis—Fludarabine—lymphatic system cancer	0.00564	0.00578	CcSEcCtD
Fulvestrant—Hepatic failure—Vincristine—lymphatic system cancer	0.00558	0.00572	CcSEcCtD
Fulvestrant—Vaginal discharge—Methotrexate—lymphatic system cancer	0.00551	0.00565	CcSEcCtD
Fulvestrant—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00541	0.00555	CcSEcCtD
Fulvestrant—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00541	0.219	CbGbCtD
Fulvestrant—Anaemia—Teniposide—lymphatic system cancer	0.0052	0.00533	CcSEcCtD
Fulvestrant—Leukopenia—Teniposide—lymphatic system cancer	0.00504	0.00516	CcSEcCtD
Fulvestrant—Pain in extremity—Vincristine—lymphatic system cancer	0.00502	0.00514	CcSEcCtD
Fulvestrant—Malnutrition—Fludarabine—lymphatic system cancer	0.00494	0.00507	CcSEcCtD
Fulvestrant—Chest pain—Teniposide—lymphatic system cancer	0.00479	0.00491	CcSEcCtD
Fulvestrant—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00459	0.0047	CcSEcCtD
Fulvestrant—Anaemia—Fludarabine—lymphatic system cancer	0.00457	0.00469	CcSEcCtD
Fulvestrant—Infection—Teniposide—lymphatic system cancer	0.00456	0.00468	CcSEcCtD
Fulvestrant—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00444	0.00455	CcSEcCtD
Fulvestrant—Leukopenia—Fludarabine—lymphatic system cancer	0.00443	0.00454	CcSEcCtD
Fulvestrant—Pruritus—Mechlorethamine—lymphatic system cancer	0.00441	0.00452	CcSEcCtD
Fulvestrant—Anorexia—Teniposide—lymphatic system cancer	0.00438	0.00449	CcSEcCtD
Fulvestrant—Cough—Fludarabine—lymphatic system cancer	0.00431	0.00442	CcSEcCtD
Fulvestrant—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00426	0.00437	CcSEcCtD
Fulvestrant—Arthralgia—Fludarabine—lymphatic system cancer	0.00421	0.00432	CcSEcCtD
Fulvestrant—Myalgia—Fludarabine—lymphatic system cancer	0.00421	0.00432	CcSEcCtD
Fulvestrant—Haemoglobin—Bleomycin—lymphatic system cancer	0.00419	0.00429	CcSEcCtD
Fulvestrant—Haemorrhage—Bleomycin—lymphatic system cancer	0.00416	0.00427	CcSEcCtD
Fulvestrant—Dyspnoea—Teniposide—lymphatic system cancer	0.00409	0.0042	CcSEcCtD
Fulvestrant—Depression—Carmustine—lymphatic system cancer	0.00404	0.00414	CcSEcCtD
Fulvestrant—Infection—Fludarabine—lymphatic system cancer	0.00401	0.00411	CcSEcCtD
Fulvestrant—Decreased appetite—Teniposide—lymphatic system cancer	0.00399	0.00409	CcSEcCtD
Fulvestrant—Vomiting—Mechlorethamine—lymphatic system cancer	0.00396	0.00406	CcSEcCtD
Fulvestrant—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00396	0.00406	CcSEcCtD
Fulvestrant—Urinary tract infection—Carmustine—lymphatic system cancer	0.00394	0.00404	CcSEcCtD
Fulvestrant—Rash—Mechlorethamine—lymphatic system cancer	0.00393	0.00403	CcSEcCtD
Fulvestrant—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00392	0.00402	CcSEcCtD
Fulvestrant—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0039	0.004	CcSEcCtD
Fulvestrant—Depression—Vincristine—lymphatic system cancer	0.00385	0.00395	CcSEcCtD
Fulvestrant—Anorexia—Fludarabine—lymphatic system cancer	0.00385	0.00394	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00375	0.00385	CcSEcCtD
Fulvestrant—CYP3A4—Vincristine—lymphatic system cancer	0.00372	0.151	CbGbCtD
Fulvestrant—Sweating—Vincristine—lymphatic system cancer	0.00371	0.0038	CcSEcCtD
Fulvestrant—Nausea—Mechlorethamine—lymphatic system cancer	0.0037	0.00379	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00368	0.00377	CcSEcCtD
Fulvestrant—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00366	0.00375	CcSEcCtD
Fulvestrant—Haemoglobin—Carmustine—lymphatic system cancer	0.00365	0.00375	CcSEcCtD
Fulvestrant—Urticaria—Teniposide—lymphatic system cancer	0.00365	0.00374	CcSEcCtD
Fulvestrant—Haemorrhage—Carmustine—lymphatic system cancer	0.00363	0.00373	CcSEcCtD
Fulvestrant—Abdominal pain—Teniposide—lymphatic system cancer	0.00363	0.00372	CcSEcCtD
Fulvestrant—Body temperature increased—Teniposide—lymphatic system cancer	0.00363	0.00372	CcSEcCtD
Fulvestrant—Paraesthesia—Fludarabine—lymphatic system cancer	0.00362	0.00371	CcSEcCtD
Fulvestrant—Sweating—Mitoxantrone—lymphatic system cancer	0.00361	0.0037	CcSEcCtD
Fulvestrant—Dyspnoea—Fludarabine—lymphatic system cancer	0.0036	0.00369	CcSEcCtD
Fulvestrant—Oedema peripheral—Carmustine—lymphatic system cancer	0.00358	0.00367	CcSEcCtD
Fulvestrant—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00357	0.00366	CcSEcCtD
Fulvestrant—Dyspepsia—Fludarabine—lymphatic system cancer	0.00355	0.00364	CcSEcCtD
Fulvestrant—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00354	0.00363	CcSEcCtD
Fulvestrant—Decreased appetite—Fludarabine—lymphatic system cancer	0.00351	0.0036	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00348	0.00357	CcSEcCtD
Fulvestrant—Fatigue—Fludarabine—lymphatic system cancer	0.00348	0.00357	CcSEcCtD
Fulvestrant—Inflammation—Methotrexate—lymphatic system cancer	0.00346	0.00354	CcSEcCtD
Fulvestrant—Pain—Fludarabine—lymphatic system cancer	0.00345	0.00354	CcSEcCtD
Fulvestrant—Constipation—Fludarabine—lymphatic system cancer	0.00345	0.00354	CcSEcCtD
Fulvestrant—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00341	0.0035	CcSEcCtD
Fulvestrant—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0034	0.00348	CcSEcCtD
Fulvestrant—Hypersensitivity—Teniposide—lymphatic system cancer	0.00338	0.00347	CcSEcCtD
Fulvestrant—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00338	0.00346	CcSEcCtD
Fulvestrant—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00338	0.00346	CcSEcCtD
Fulvestrant—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00335	0.00344	CcSEcCtD
Fulvestrant—Anaemia—Bleomycin—lymphatic system cancer	0.00335	0.00344	CcSEcCtD
Fulvestrant—Asthenia—Teniposide—lymphatic system cancer	0.00329	0.00338	CcSEcCtD
Fulvestrant—Pruritus—Teniposide—lymphatic system cancer	0.00325	0.00333	CcSEcCtD
Fulvestrant—Leukopenia—Bleomycin—lymphatic system cancer	0.00324	0.00333	CcSEcCtD
Fulvestrant—Body temperature increased—Fludarabine—lymphatic system cancer	0.00319	0.00327	CcSEcCtD
Fulvestrant—Malnutrition—Carmustine—lymphatic system cancer	0.00316	0.00324	CcSEcCtD
Fulvestrant—Cough—Bleomycin—lymphatic system cancer	0.00316	0.00324	CcSEcCtD
Fulvestrant—Angiopathy—Vincristine—lymphatic system cancer	0.00315	0.00323	CcSEcCtD
Fulvestrant—Diarrhoea—Teniposide—lymphatic system cancer	0.00314	0.00322	CcSEcCtD
Fulvestrant—Chest pain—Bleomycin—lymphatic system cancer	0.00309	0.00316	CcSEcCtD
Fulvestrant—Myalgia—Bleomycin—lymphatic system cancer	0.00309	0.00316	CcSEcCtD
Fulvestrant—Back pain—Carmustine—lymphatic system cancer	0.00306	0.00314	CcSEcCtD
Fulvestrant—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00297	0.00305	CcSEcCtD
Fulvestrant—Infection—Bleomycin—lymphatic system cancer	0.00294	0.00301	CcSEcCtD
Fulvestrant—Anaemia—Carmustine—lymphatic system cancer	0.00292	0.003	CcSEcCtD
Fulvestrant—Back pain—Vincristine—lymphatic system cancer	0.00292	0.003	CcSEcCtD
Fulvestrant—Vomiting—Teniposide—lymphatic system cancer	0.00292	0.00299	CcSEcCtD
Fulvestrant—Asthenia—Fludarabine—lymphatic system cancer	0.00289	0.00297	CcSEcCtD
Fulvestrant—Rash—Teniposide—lymphatic system cancer	0.00289	0.00297	CcSEcCtD
Fulvestrant—Dermatitis—Teniposide—lymphatic system cancer	0.00289	0.00297	CcSEcCtD
Fulvestrant—Headache—Teniposide—lymphatic system cancer	0.00288	0.00295	CcSEcCtD
Fulvestrant—Pruritus—Fludarabine—lymphatic system cancer	0.00285	0.00293	CcSEcCtD
Fulvestrant—Back pain—Mitoxantrone—lymphatic system cancer	0.00285	0.00292	CcSEcCtD
Fulvestrant—Leukopenia—Carmustine—lymphatic system cancer	0.00283	0.0029	CcSEcCtD
Fulvestrant—Anorexia—Bleomycin—lymphatic system cancer	0.00282	0.00289	CcSEcCtD
Fulvestrant—Anaemia—Vincristine—lymphatic system cancer	0.00279	0.00286	CcSEcCtD
Fulvestrant—Diarrhoea—Fludarabine—lymphatic system cancer	0.00276	0.00283	CcSEcCtD
Fulvestrant—Nausea—Teniposide—lymphatic system cancer	0.00273	0.0028	CcSEcCtD
Fulvestrant—Anaemia—Mitoxantrone—lymphatic system cancer	0.00272	0.00279	CcSEcCtD
Fulvestrant—Vertigo—Vincristine—lymphatic system cancer	0.00271	0.00278	CcSEcCtD
Fulvestrant—Hepatic failure—Methotrexate—lymphatic system cancer	0.00271	0.00278	CcSEcCtD
Fulvestrant—Leukopenia—Vincristine—lymphatic system cancer	0.0027	0.00277	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0027	0.00276	CcSEcCtD
Fulvestrant—Myalgia—Carmustine—lymphatic system cancer	0.00269	0.00276	CcSEcCtD
Fulvestrant—Chest pain—Carmustine—lymphatic system cancer	0.00269	0.00276	CcSEcCtD
Fulvestrant—Anxiety—Carmustine—lymphatic system cancer	0.00268	0.00275	CcSEcCtD
Fulvestrant—Paraesthesia—Bleomycin—lymphatic system cancer	0.00266	0.00272	CcSEcCtD
Fulvestrant—Dyspnoea—Bleomycin—lymphatic system cancer	0.00264	0.0027	CcSEcCtD
Fulvestrant—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00263	0.0027	CcSEcCtD
Fulvestrant—Decreased appetite—Bleomycin—lymphatic system cancer	0.00257	0.00264	CcSEcCtD
Fulvestrant—Myalgia—Vincristine—lymphatic system cancer	0.00257	0.00264	CcSEcCtD
Fulvestrant—Cough—Mitoxantrone—lymphatic system cancer	0.00257	0.00263	CcSEcCtD
Fulvestrant—Infection—Carmustine—lymphatic system cancer	0.00257	0.00263	CcSEcCtD
Fulvestrant—Vomiting—Fludarabine—lymphatic system cancer	0.00257	0.00263	CcSEcCtD
Fulvestrant—Rash—Fludarabine—lymphatic system cancer	0.00254	0.00261	CcSEcCtD
Fulvestrant—Dermatitis—Fludarabine—lymphatic system cancer	0.00254	0.00261	CcSEcCtD
Fulvestrant—Pain—Bleomycin—lymphatic system cancer	0.00253	0.00259	CcSEcCtD
Fulvestrant—Headache—Fludarabine—lymphatic system cancer	0.00253	0.00259	CcSEcCtD
Fulvestrant—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0025	0.00257	CcSEcCtD
Fulvestrant—Myalgia—Mitoxantrone—lymphatic system cancer	0.0025	0.00257	CcSEcCtD
Fulvestrant—Chest pain—Mitoxantrone—lymphatic system cancer	0.0025	0.00257	CcSEcCtD
Fulvestrant—Anxiety—Mitoxantrone—lymphatic system cancer	0.0025	0.00256	CcSEcCtD
Fulvestrant—Anorexia—Carmustine—lymphatic system cancer	0.00246	0.00252	CcSEcCtD
Fulvestrant—Infection—Vincristine—lymphatic system cancer	0.00245	0.00251	CcSEcCtD
Fulvestrant—Nervous system disorder—Vincristine—lymphatic system cancer	0.00242	0.00248	CcSEcCtD
Fulvestrant—Nausea—Fludarabine—lymphatic system cancer	0.0024	0.00246	CcSEcCtD
Fulvestrant—Infection—Mitoxantrone—lymphatic system cancer	0.00238	0.00245	CcSEcCtD
Fulvestrant—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00238	0.00244	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00235	0.00241	CcSEcCtD
Fulvestrant—Urticaria—Bleomycin—lymphatic system cancer	0.00235	0.00241	CcSEcCtD
Fulvestrant—Anorexia—Vincristine—lymphatic system cancer	0.00235	0.00241	CcSEcCtD
Fulvestrant—Body temperature increased—Bleomycin—lymphatic system cancer	0.00234	0.0024	CcSEcCtD
Fulvestrant—Insomnia—Carmustine—lymphatic system cancer	0.00234	0.00239	CcSEcCtD
Fulvestrant—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00233	0.00239	CcSEcCtD
Fulvestrant—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00232	0.00238	CcSEcCtD
Fulvestrant—Paraesthesia—Carmustine—lymphatic system cancer	0.00232	0.00238	CcSEcCtD
Fulvestrant—Dyspnoea—Carmustine—lymphatic system cancer	0.0023	0.00236	CcSEcCtD
Fulvestrant—Anorexia—Mitoxantrone—lymphatic system cancer	0.00229	0.00235	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00225	0.0023	CcSEcCtD
Fulvestrant—Decreased appetite—Carmustine—lymphatic system cancer	0.00224	0.0023	CcSEcCtD
Fulvestrant—Insomnia—Vincristine—lymphatic system cancer	0.00223	0.00229	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00223	0.00229	CcSEcCtD
Fulvestrant—Paraesthesia—Vincristine—lymphatic system cancer	0.00221	0.00227	CcSEcCtD
Fulvestrant—Pain—Carmustine—lymphatic system cancer	0.00221	0.00226	CcSEcCtD
Fulvestrant—Constipation—Carmustine—lymphatic system cancer	0.00221	0.00226	CcSEcCtD
Fulvestrant—Breast disorder—Methotrexate—lymphatic system cancer	0.0022	0.00225	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00219	0.00224	CcSEcCtD
Fulvestrant—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00218	0.00223	CcSEcCtD
Fulvestrant—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00216	0.00221	CcSEcCtD
Fulvestrant—Decreased appetite—Vincristine—lymphatic system cancer	0.00214	0.0022	CcSEcCtD
Fulvestrant—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00214	0.00219	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00213	0.00218	CcSEcCtD
Fulvestrant—Fatigue—Vincristine—lymphatic system cancer	0.00213	0.00218	CcSEcCtD
Fulvestrant—Asthenia—Bleomycin—lymphatic system cancer	0.00212	0.00218	CcSEcCtD
Fulvestrant—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00211	0.00217	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00211	0.00217	CcSEcCtD
Fulvestrant—Pain—Vincristine—lymphatic system cancer	0.00211	0.00216	CcSEcCtD
Fulvestrant—Constipation—Vincristine—lymphatic system cancer	0.00211	0.00216	CcSEcCtD
Fulvestrant—Pruritus—Bleomycin—lymphatic system cancer	0.00209	0.00215	CcSEcCtD
Fulvestrant—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00209	0.00214	CcSEcCtD
Fulvestrant—Fatigue—Mitoxantrone—lymphatic system cancer	0.00207	0.00212	CcSEcCtD
Fulvestrant—Pain—Mitoxantrone—lymphatic system cancer	0.00205	0.0021	CcSEcCtD
Fulvestrant—Constipation—Mitoxantrone—lymphatic system cancer	0.00205	0.0021	CcSEcCtD
Fulvestrant—Body temperature increased—Carmustine—lymphatic system cancer	0.00204	0.00209	CcSEcCtD
Fulvestrant—Abdominal pain—Carmustine—lymphatic system cancer	0.00204	0.00209	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00202	0.00207	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00196	0.00201	CcSEcCtD
Fulvestrant—Body temperature increased—Vincristine—lymphatic system cancer	0.00195	0.002	CcSEcCtD
Fulvestrant—Abdominal pain—Vincristine—lymphatic system cancer	0.00195	0.002	CcSEcCtD
Fulvestrant—Urticaria—Mitoxantrone—lymphatic system cancer	0.00191	0.00196	CcSEcCtD
Fulvestrant—Hypersensitivity—Carmustine—lymphatic system cancer	0.0019	0.00195	CcSEcCtD
Fulvestrant—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0019	0.00195	CcSEcCtD
Fulvestrant—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0019	0.00195	CcSEcCtD
Fulvestrant—Vomiting—Bleomycin—lymphatic system cancer	0.00188	0.00193	CcSEcCtD
Fulvestrant—Infestation NOS—Methotrexate—lymphatic system cancer	0.00188	0.00192	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—lymphatic system cancer	0.00188	0.00192	CcSEcCtD
Fulvestrant—Depression—Methotrexate—lymphatic system cancer	0.00187	0.00192	CcSEcCtD
Fulvestrant—Rash—Bleomycin—lymphatic system cancer	0.00187	0.00191	CcSEcCtD
Fulvestrant—Dermatitis—Bleomycin—lymphatic system cancer	0.00186	0.00191	CcSEcCtD
Fulvestrant—Asthenia—Carmustine—lymphatic system cancer	0.00185	0.0019	CcSEcCtD
Fulvestrant—Hypersensitivity—Vincristine—lymphatic system cancer	0.00182	0.00186	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—lymphatic system cancer	0.0018	0.00184	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00177	0.00182	CcSEcCtD
Fulvestrant—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00177	0.00181	CcSEcCtD
Fulvestrant—Asthenia—Vincristine—lymphatic system cancer	0.00177	0.00181	CcSEcCtD
Fulvestrant—Diarrhoea—Carmustine—lymphatic system cancer	0.00177	0.00181	CcSEcCtD
Fulvestrant—Nausea—Bleomycin—lymphatic system cancer	0.00176	0.0018	CcSEcCtD
Fulvestrant—Asthenia—Mitoxantrone—lymphatic system cancer	0.00172	0.00177	CcSEcCtD
Fulvestrant—Dizziness—Carmustine—lymphatic system cancer	0.00171	0.00175	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—lymphatic system cancer	0.00169	0.00173	CcSEcCtD
Fulvestrant—Diarrhoea—Vincristine—lymphatic system cancer	0.00169	0.00173	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—lymphatic system cancer	0.00168	0.00173	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—lymphatic system cancer	0.00168	0.00173	CcSEcCtD
Fulvestrant—Pharyngitis—Methotrexate—lymphatic system cancer	0.00167	0.00171	CcSEcCtD
Fulvestrant—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00164	0.00168	CcSEcCtD
Fulvestrant—Vomiting—Carmustine—lymphatic system cancer	0.00164	0.00168	CcSEcCtD
Fulvestrant—Dizziness—Vincristine—lymphatic system cancer	0.00163	0.00167	CcSEcCtD
Fulvestrant—Rash—Carmustine—lymphatic system cancer	0.00163	0.00167	CcSEcCtD
Fulvestrant—Dermatitis—Carmustine—lymphatic system cancer	0.00163	0.00167	CcSEcCtD
Fulvestrant—Headache—Carmustine—lymphatic system cancer	0.00162	0.00166	CcSEcCtD
Fulvestrant—Vomiting—Vincristine—lymphatic system cancer	0.00157	0.00161	CcSEcCtD
Fulvestrant—Rash—Vincristine—lymphatic system cancer	0.00155	0.00159	CcSEcCtD
Fulvestrant—Dermatitis—Vincristine—lymphatic system cancer	0.00155	0.00159	CcSEcCtD
Fulvestrant—Headache—Vincristine—lymphatic system cancer	0.00154	0.00158	CcSEcCtD
Fulvestrant—Nausea—Carmustine—lymphatic system cancer	0.00153	0.00157	CcSEcCtD
Fulvestrant—Angiopathy—Methotrexate—lymphatic system cancer	0.00153	0.00157	CcSEcCtD
Fulvestrant—Vomiting—Mitoxantrone—lymphatic system cancer	0.00153	0.00157	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—lymphatic system cancer	0.00152	0.00156	CcSEcCtD
Fulvestrant—Rash—Mitoxantrone—lymphatic system cancer	0.00151	0.00155	CcSEcCtD
Fulvestrant—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00151	0.00155	CcSEcCtD
Fulvestrant—Headache—Mitoxantrone—lymphatic system cancer	0.0015	0.00154	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—lymphatic system cancer	0.00147	0.0015	CcSEcCtD
Fulvestrant—Nausea—Vincristine—lymphatic system cancer	0.00146	0.0015	CcSEcCtD
Fulvestrant—Nausea—Mitoxantrone—lymphatic system cancer	0.00143	0.00146	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—lymphatic system cancer	0.00142	0.00145	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—lymphatic system cancer	0.00135	0.00139	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—lymphatic system cancer	0.00132	0.00135	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—lymphatic system cancer	0.00131	0.00135	CcSEcCtD
Fulvestrant—Cough—Methotrexate—lymphatic system cancer	0.00128	0.00131	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—lymphatic system cancer	0.00125	0.00128	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—lymphatic system cancer	0.00125	0.00128	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—lymphatic system cancer	0.00125	0.00128	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00124	0.00127	CcSEcCtD
Fulvestrant—Infection—Methotrexate—lymphatic system cancer	0.00119	0.00122	CcSEcCtD
Fulvestrant—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00117	0.0012	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—lymphatic system cancer	0.00116	0.00119	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00116	0.00119	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—lymphatic system cancer	0.00114	0.00117	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00109	0.00112	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—lymphatic system cancer	0.00108	0.00111	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—lymphatic system cancer	0.00107	0.00109	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—lymphatic system cancer	0.00105	0.00108	CcSEcCtD
Fulvestrant—Decreased appetite—Methotrexate—lymphatic system cancer	0.00104	0.00107	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00103	0.00106	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—lymphatic system cancer	0.00103	0.00106	CcSEcCtD
Fulvestrant—Pain—Methotrexate—lymphatic system cancer	0.00102	0.00105	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000978	0.001	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—lymphatic system cancer	0.00095	0.000974	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—lymphatic system cancer	0.000946	0.000969	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—lymphatic system cancer	0.000946	0.000969	CcSEcCtD
Fulvestrant—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000881	0.000904	CcSEcCtD
Fulvestrant—Asthenia—Methotrexate—lymphatic system cancer	0.000858	0.00088	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—lymphatic system cancer	0.000846	0.000868	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—lymphatic system cancer	0.000818	0.000839	CcSEcCtD
Fulvestrant—Dizziness—Methotrexate—lymphatic system cancer	0.000791	0.000811	CcSEcCtD
Fulvestrant—Vomiting—Methotrexate—lymphatic system cancer	0.00076	0.00078	CcSEcCtD
Fulvestrant—Rash—Methotrexate—lymphatic system cancer	0.000754	0.000773	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—lymphatic system cancer	0.000753	0.000773	CcSEcCtD
Fulvestrant—Headache—Methotrexate—lymphatic system cancer	0.000749	0.000768	CcSEcCtD
Fulvestrant—Nausea—Methotrexate—lymphatic system cancer	0.00071	0.000728	CcSEcCtD
